Thursday, June 20, 2019 - 07:00

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), today announced that it will host a key opinion leader (KOL) call focused on the topic of IPH4102 “TELLOMAK” clinical trial design and rationale in T-cell lymphoma, including preclinical data in peripheral T-cell lymphoma (PTCL) today, Thursday, June 20, at 2pm CEST / 8am ET.

The call will feature a presentation by Dr. Pierluigi Porcu, MD, key opinion leader and Principal Investigator of the TELLOMAK study. He will discuss the cutaneous T-cell lymphoma (CTCL) and PTCL treatment landscapes and rationale of the TELLOMAK trial design. Innate's Chief Medical Officer, Pierre Dodion, MD, will also provide strategic perspectives on IPH4102’s development.

Prof. Pierluigi Porcu is Director of the Division of Medical Oncology and Hematopoietic Stem Cell Transplantation at the Jefferson University Hospital in Philadelphia, PA, USA. Prof. Porcu is a Lymphoma-focused hematologic oncologist with a long track record of advocacy and education for patients with cutaneous lymphoma.

To view the presentation and posters presented at the International Conference on Malignant Lymphoma (“ICML”) visit: https://www.innate-pharma.com/en/actus/evenements/icml-2019-lugano-switzerland

 

KOL webcast and conference call on Thursday, June 20, at 2pm CEST (8am ET)

The presentation and access to the live webcast will be available at this link: https://edge.media-server.com/m6/p/sq5czucf

Participants can also join the conference call using the following dial-in numbers:

Location

Phone number

France

+33 (0) 176700794

United Kingdom, International

+44 (0) 2071 928000

Switzerland

+41 (0) 315800059

United States

+1 631-510-7495

The participation code is: 9493234

Replay of the webcast : https://edge.media-server.com/m6/p/sq5czucf